XBiotech Inc
Slēgts
2.31
Pārskats
Akcijas cenas izmaiņa
24h
Min
2.26
Max
2.34
Ienākumi | 21M -5.5M |
|---|---|
EPS | -0.181 |
Darbinieki | 87 |
EBITDA | 24M -5.1M |
Nākamie ieņēmumi | 2026. g. 11. aug. |
|---|
Tirgus kapitalizācija | -4.9M 70M |
|---|---|
Iepriekšējā atvēršanas cena | 2.31 |
Iepriekšējā slēgšanas cena | 2.31 |
XBiotech Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.